Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-12
2010-02-02
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07655684
ABSTRACT:
Compounds that act as inhibitors of QC including those represented by the general formulae 1 to 9:and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Corea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
REFERENCES:
patent: 5552426 (1996-09-01), Lunn et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 93/001812 (1993-02-01), None
patent: 93/020061 (1993-10-01), None
patent: 95/022327 (1995-08-01), None
patent: 99/041220 (1999-08-01), None
patent: 99/041224 (1999-08-01), None
patent: 00/05053596 (2000-09-01), None
patent: 00/05053596 (2000-09-01), None
patent: 02/013821 (2002-02-01), None
patent: 03/0070732 (2003-08-01), None
patent: 04/089366 (2004-10-01), None
patent: 04/098591 (2004-11-01), None
Clader, John W. et al., Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups on in Vitro and in Vivo Activity, J. Med Chem 1995, 38, 1600-1607.
Ganelin, C. Robin et al, Design of potent non-thiourea H3-Receptor histamine antagonists, J. Med Chem. 1995, 38 3342-3350.
Liu, Shenquan et al., Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas J. Med Chem. 1998, 41, 4693-4705.
Misquitta, Stephanie A. et al., Inhibitions Studies of Glutaminyl Cyclase, FASEB Journal 2001.
Misquitta, Stephanie A. et al., Characterization of the inhibition of glutaminyl cyclase by imidozole derivatives and phenathorolines, FASEB Annual meeting, 2002.
Moon, Malcolm et al. Cholinergic activity and acetylenic imidazoles and related compounds J. Med. Chem 1991, 34, 2314-2327.
Schilling, Stephan et al., Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions, FEBS Letters 563, 2004, 191-196.
Venkatachalam, T.K. et al., Anti-HIV activity of aromatic and heterocylic thiazolyl thiourea compounds, Bioorganic & Medicinal Chemistry Letters 2001, 11, 523-528.
Wright, William B. et al., Thromboxane synthetase inhibitors and antihypertensive agents. J. Med. Chem 1986, 29, 523-530.
Wright, William B. et al., Thromboxane synthetase inhibitors and antihypertensive agents. J. Med. Chem 1987, 30, 2277-2283.
Buchholz Mirko
Demuth Hans-Ulrich
Heiser Ulrich
Niestroj André Johannes
Schilling Stephan
Probiodrug (AG)
Sonnenschein Nath & Rosenthal LLP
Stockton Laura L.
LandOfFree
Inhibitors of glutaminyl cyclase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glutaminyl cyclase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glutaminyl cyclase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197121